MARKET

TEVA

TEVA

Teva Pharm Ind
NYSE

Real-time Quotes | Nasdaq Last Sale

10.35
-0.24
-2.22%
Opening 10:53 03/05 EST
OPEN
10.55
PREV CLOSE
10.58
HIGH
10.77
LOW
10.25
VOLUME
3.01M
TURNOVER
--
52 WEEK HIGH
13.30
52 WEEK LOW
6.25
MARKET CAP
11.34B
P/E (TTM)
-2.8413
1D
5D
1M
3M
1Y
5Y
Teva slides as EU starts antitrust probe into Copaxone sales
Teva Pharmaceutical (TEVA) has lost ~1.7% in the premarket on the reports of an investigation started by the EU antitrust regulators on whether the company had illegally hindered rivals to access its multiple sclerosis
Seekingalpha · 1d ago
Teva’s EU Antitrust Probe to Check If It Talked Down Rival Drugs
European Union antitrust regulators are investigating whether Teva Pharmaceutical Industries Ltd. tried to hinder rival makers of a multiple sclerosis drug, including waging a campaign to talk down generic versions the product.
Bloomberg · 1d ago
Novartis Lends Support To Manufacture CureVac's COVID-19 Shots
Benzinga · 1d ago
EU investigating Teva for blocking rivals to multiple sclerosis drug
Israeli drugmaker Teva is being investigated by EU antitrust regulators who are looking into whether it illegally hindered rivals' access to its multiple sclerosis medicine Copaxone.
Reuters · 1d ago
Carisoprodol Tablets Market to see Huge Growth by 2026 | Mylan, Carlsbad Tech, Astral Pharmaceuticals, Taj Pharma
Mar 04, 2021 (Market Insight Reports) -- Carisoprodol Tablets Market Comprehensive Study is an expert and top to bottom investigation on the momentum...
Market Insight Reports · 1d ago
Insomnia Therapeutics Drugs Market Includes Top Countries Figures, Business Growth, Market Size, Swot Analysis, Business Opportunity, Applications, Trends and Forecast to 2027
The Express Wire · 1d ago
2021-2027 Global Benign Prostatic Hyperplasia Therapeutics Market: Industry Share, Leading Players Strategy, Development Plans, Emerging Demand, Healthy CAGR, Drivers and Opportunity Outlook | 360 Research Report
Mar 04, 2021 (The Expresswire) -- “Benign Prostatic Hyperplasia Therapeutics Market" Forecast 2021-2027: Treatment of patients with obstructive benign...
The Express Wire · 1d ago
Global Lysosomal Acid Liapse (LAL) Deficiency Treatment Market Outlook, Industry Analysis and Prospect 2020 -2026
Mar 04, 2021 (Heraldkeepers) -- The growing adoption of enzyme replacement therapy for treatment is one of the major factors driving the growth of global...
Heraldkeepers · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TEVA. Analyze the recent business situations of Teva Pharm Ind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 25 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TEVA stock price target is 12.35 with a high estimate of 17.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 759
Institutional Holdings: 608.06M
% Owned: 55.45%
Shares Outstanding: 1.10B
TypeInstitutionsShares
Increased
124
25.33M
New
111
4.18M
Decreased
152
25.53M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.39%
Pharmaceuticals & Medical Research
-1.12%
Key Executives
Chairman/Independent Director
Sol Barer
President/Chief Executive Officer/Director
Kaare Schultz
Chief Financial Officer/Executive Vice President/Director
Eli Kalif
Chief Financial Officer/Executive Vice President
Eliyahu Kalif
Chief Human Resource Officer/Executive Vice President
Mark Sabag
Executive Vice President
Richard Daniell
Executive Vice President
Sven Dethlefs
Executive Vice President
Eric Drape
Executive Vice President
Hafrun Fridriksdottir
Executive Vice President
Gianfranco Nazzi
Executive Vice President
Brendan O'Grady
Executive Vice President
David Stark
Chief Accounting Officer
Andrew Weil
Independent Director
Rosemary Crane
Independent Director
Amir Elstein
Independent Director
Jean-Michel Halfon
Independent Director
Abbas Hussain
Independent Director
Gerald Lieberman
Independent Director
Roberto Mignone
Independent Director
Perry Nisen
Independent Director
Nechemia Peres
Independent Director
Ronit Satchi-Fainaro
Independent Director
Janet Vergis
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.072
11/27/2017
08/04/2017
Dividend USD 0.072
08/25/2017
05/16/2017
Dividend USD 0.289
06/01/2017
03/16/2017
Dividend USD 0.289
02/28/2017
11/17/2016
Dividend USD 0.289
12/01/2016
08/08/2016
Dividend USD 0.289
08/18/2016
05/11/2016
Dividend USD 0.289
05/20/2016
02/16/2016
Dividend USD 0.289
02/25/2016
11/02/2015
Dividend USD 0.289
11/13/2015
07/31/2015
Dividend USD 0.289
08/18/2015
05/05/2015
Dividend USD 0.289
05/15/2015
02/20/2015
Dividend USD 0.294
02/17/2015
11/18/2014
Dividend USD 0.27
11/13/2014
08/25/2014
Dividend USD 0.291
08/19/2014
05/20/2014
Dividend USD 0.298
05/16/2014
03/05/2014
Dividend USD 0.293
02/20/2014
11/21/2013
Dividend USD 0.278
11/18/2013
08/21/2013
Dividend USD 0.274
08/16/2013
  • All
  • Financials
  • Insiders
More
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Webull offers kinds of Teva Pharmaceutical Industries Ltd (ADR) stock information, including NYSE:TEVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TEVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TEVA stock methods without spending real money on the virtual paper trading platform.